Ads
related to: cancer, zytiga- Dosing & Administration
See Recommended NUBEQA® Dosage And
Learn About Drug Interactions Here.
- Clinical Information
Read About A Double-Blind, Placebo-
Controlled, Randomized Study.
- Contact A Bayer Rep
Stay Informed On Everything NUBEQA®
By Contacting A Bayer Rep Today.
- Patient Profiles
Explore Patient Profiles To See If
NUBEQA® May Be The Right Option.
- Downloadable Resources
Resources For Physicians & Patients
Available On The Site To Download.
- Second NUBEQA® Indication
NUBEQA® Treats 2 Indications
Get The Data You Need
- Dosing & Administration
Search results
AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use
Zacks via Yahoo Finance· 1 year agoAstraZeneca AZN and partner Merck MRK announced that the Committee for Medicinal Products for Human...
Biden touts next steps on 'Cancer Moonshot' in speech at JFK library
NBC News via Yahoo News· 2 years agoBiden will announce steps to expand on his "Cancer Moonshot" initiative to prevent deaths from the...
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
Zacks via Yahoo Finance· 1 year agoThe FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for...
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
Zacks via Yahoo Finance· 8 months agoAstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to...
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
Zacks via Yahoo Finance· 1 year agoAstraZeneca AZN announced an agreement to acquire private biotech, Neogene Therapeutics to build its...
Prostate Cancer
Verywell Health via Yahoo News· 1 year agoProstate cancer is the most commonly diagnosed cancer in males, with risk factors including advanced age and a family history of the condition....
Point radiopharma drug results disappoint in prostate cancer study
BioPharma Dive via Yahoo Finance· 5 months agoDive Brief: A targeted radiation drug being developed by Indianapolis-based Point BioPharma met its...
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
Zacks via Yahoo Finance· 1 year agoEli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based...
J&J to buy targeted cancer therapy developer Ambrx for $2 billion
Reuters via Yahoo Finance· 4 months agoJ&J will pay $28 per share of Ambrx, which represents a premium of about 105% to the stock's last...
Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK
Zacks via Yahoo Finance· 2 years agoSanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung...
Ads
related to: cancer, zytiga
